Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04765059 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 98
- Enrollment target
- 20
- Study locations
NCT04765059 is a Phase 3 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 98 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT04765059, a Phase 3 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 98 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study will evaluate the efficacy and safety of treatment with chemotherapy in combination with osimertinib compared to chemotherapy in combination with placebo in patients whose disease has progressed extracranially following first-line osimertinib treatment.
Conditions Studied
Interventions
- DRUG Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
- DRUG Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
Study Locations (20)
Other
- Research Site - Beijing
- Research Site - Beijing
- Research Site - Ganzhou
- Research Site - Guangzhou
- Research Site - Jinan
- Research Site - Shenyang
- Research Site - Tianjin
- Research Site - Zhengzhou
- Research Site - Berlin
- Research Site - Cologne
- Research Site - Cologne
- Research Site - Hanover
- Research Site - München
- Research Site - Beersheba
- Research Site - Jerusalem
- Research Site - Jerusalem
- Research Site - Kfar Saba
- Research Site - Tel Aviv
Maryland
- Research Site - Silver Spring
Massachusetts
- Research Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2021-09-12 |
| Est. Completion | 2026-06-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04765059
The ClinicalTrials.gov registry entry for NCT04765059 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (85% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin is the first listed.
NCT04765059 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Other, Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04765059 about?
NCT04765059 is a clinical study titled "A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)". The study will evaluate the efficacy and safety of treatment with chemotherapy in combination with osimertinib compared to chemotherapy in combination with placebo in patients whose disease has progressed extracranially following first-line osimertinib treatment.
What is the current status of trial NCT04765059?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 98 participants. The study started on 2021-09-12. Estimated completion is 2026-06-02.
What conditions does trial NCT04765059 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT04765059?
The interventions under investigation include: Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin (DRUG), Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin (DRUG).
Who is sponsoring clinical trial NCT04765059?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04765059 being conducted?
This trial has 20 study locations across Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.